
Definition
Neurotransmitters are chemical messengers that neurons release at a synapse to signal other neurons, muscles or glands. The main ones students meet are dopamine, serotonin, norepinephrine, GABA, glutamate and acetylcholine. They take part in mood, attention, movement, learning and memory, but no behavior or disorder is explained by a single one.
In a neuroscience class someone raises a hand and asks the question every psychology student eventually asks: if low serotonin causes depression, doesn't raising it fix it? The instructor answers that behavior is not explained by one molecule but by systems that interact. It is a frustrating answer until you see why it is the accurate one.
It is written for psychology students who have already covered synapses and want a functional translation of neurochemistry into behavior. That matters because popular writing on this topic usually goes wrong in the same two sentences: "it is all dopamine" and "a chemical deficit explains depression."
Working definition. A neurotransmitter is a molecule released from a presynaptic neuron that crosses the synaptic cleft and changes the probability that the postsynaptic neuron fires. Behavior is the aggregate outcome of thousands of such exchanges happening in parallel, shaped by brain architecture, context and prior learning.
This guide gives you a working map. For each major neurotransmitter you will find what it does, how it connects to behavior, one or two well-sourced findings, and the popular oversimplification to avoid. You will also find a summary table and the mistakes that most often cost points on exams.
The short version
- A neurotransmitter is released from a presynaptic neuron, crosses the synaptic cleft and changes the likelihood that the postsynaptic neuron fires.
- Glutamate is the main excitatory transmitter and GABA the main inhibitory one in the brain.
- Dopamine, serotonin and norepinephrine are often called neuromodulators: they tune the activity of circuits that are already organized.
- Whether a transmitter excites or inhibits depends on the receptor it binds, not on the molecule alone.
- "Chemical imbalance" explanations of mental disorders are oversimplifications. Behavior emerges from circuits, learning, context and development.
Dopamine: prediction, motivation and effort
Dopamine is often called "the pleasure chemical." The research says something more specific. In recordings from dopamine neurons, activity rises when a reward is better than expected, stays near baseline when a reward arrives as predicted, and dips when an expected reward fails to appear (Schultz, 1998; Schultz et al., 1997). That pattern fits a reward prediction error: the difference between what was expected and what happened. It links dopamine to learning, which is why this finding is often connected to classical and operant conditioning.
Everyday examples show the logic. A student who postpones studying until the last minute and still passes may be learning that the reward arrives anyway: the prediction is confirmed, so the habit is reinforced. In depression, a drop in starting activities is often described as a loss of anticipated pleasure, and dopamine-based accounts of motivation offer one way to think about it. In both cases what changes is expectation and the drive to move toward a reward, not simply the capacity to feel good. That is why dopamine is closely tied to intrinsic motivation and is better described as a signal about prediction than as "chemical fun."
Dopamine also seems to be about motivation more than enjoyment. Berridge and Robinson (1998, 2016) distinguish "wanting" (the motivational pull toward a reward) from "liking" (the pleasure of receiving it) and argue that dopamine is more closely tied to wanting. Related work on the nucleus accumbens suggests that dopamine helps determine how much effort an animal will invest to obtain a reward (Salamone & Correa, 2012).
The major dopamine pathways give you a map: the mesolimbic pathway (from the ventral tegmental area to the nucleus accumbens) is central to reward and motivation; the mesocortical pathway projects to the prefrontal cortex; the nigrostriatal pathway, which is involved in movement, degenerates in Parkinson's disease. That last fact illustrates a key principle: the same neurotransmitter has different functions in different circuits. Levodopa, a precursor of dopamine, improves motor symptoms in Parkinson's disease but does not stop the underlying neurodegeneration.
Technical note. The reward prediction error (Schultz, 1998) is the difference between the reward received and the reward expected. When the difference is positive, phasic dopamine activity rises; when it is negative, activity dips below baseline. Tonic dopamine, the slower background level, has been linked to how much effort an animal is willing to invest before starting a behavior (Salamone & Correa, 2012).
Popular oversimplification: "I'm addicted to dopamine." Dopamine contributes to how learned cues come to drive wanting, but pleasure involves other systems and no single chemical explains an addiction.
Serotonin: a widely acting modulator, not "the happiness molecule"
Serotonin (5-HT) takes part in mood, sleep, appetite, impulse control and sensitivity to threat, among other functions. Several features make it hard to summarize:
- Most of the body's serotonin is outside the brain. Roughly 90 percent is made in the gut, where it helps regulate gastrointestinal function (Berger et al., 2009). Saying "low serotonin" without specifying where is biologically vague.
- There are many receptor types. At least 14 serotonin receptor subtypes have been identified (Berger et al., 2009), with different distributions and effects. "Raising serotonin" is therefore not a single action.
This receptor diversity explains how a single system can take part in mood, sleep, appetite, nausea, sexual function, learning and social behavior: serotonin modulates probabilities in specific circuits, depending on which receptor is involved. The subtypes you will meet most often include 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT6 and 5-HT7, each with its own distribution, function and pharmacology.
What about depression? An umbrella review of the evidence concluded that there is no consistent support for the idea that depression is caused by low serotonin activity or concentrations (Moncrieff et al., 2022). Cowen and Browning (2015) similarly argue that what serotonin has to do with depression is still unclear. Selective serotonin reuptake inhibitors (SSRIs) block the serotonin transporter and are widely used; one line of research suggests they quickly change how people process emotional information, with mood effects appearing later (Harmer et al., 2017). The accurate summary is that serotonergic drugs can help many people, and the "low serotonin" explanation does not account for why.
A point worth keeping for supervision: when a client says "I lack serotonin," what is probably being described is a difficulty modulating negative affect. That can be approached through behavior, through pharmacology or through both, and the clinical decision does not depend on chemistry alone.
Technical note. Less than 5% of the body's serotonin is in the brain. Most of it lives in the gastrointestinal tract and in platelets. That is why talking about "low serotonin" without specifying a compartment is biologically confusing.
A practical caution: this is a discussion of theory for students. Anyone who takes a psychiatric medication should not stop or change it without talking to the prescriber.
Norepinephrine: arousal and attention
Norepinephrine (noradrenaline) is released widely from a small brainstem structure, the locus coeruleus. It adjusts arousal and attention, and it takes part in the stress response. Sara (2009) reviews how the locus coeruleus modulates cognition, and Aston-Jones and Cohen (2005) propose an influential adaptive gain theory in which the system shifts between modes that favor focused performance on a task and modes that favor exploring alternatives. Performance generally follows an inverted-U relation with arousal: moderate arousal helps, and very high arousal, as in intense stress, can impair fine attention.
Its role is better described as adjusting how broad or narrow perceptual and attentional processing is, according to the demands of the situation, than as "keeping you awake." Under moderate arousal, attentional performance tends to improve. Under excessive arousal, such as acute stress or high anxiety, performance falls, a pattern often read as the system prioritizing survival-relevant processing over fine-grained analysis.
Popular oversimplification: treating "focus" as a single chemical dial. Attention also depends on dopamine, acetylcholine, circuits in the prefrontal cortex and much else.
| System | Core function | Observable behavior | Common trap |
|---|---|---|---|
| Dopamine (mesolimbic, mesocortical) | Reward prediction, effort | Initiation, seeking, persistence | "Addicted to dopamine" |
| Serotonin (5-HT) | Affective regulation, impulsivity | Mood modulation, self-control | "The chemical deficit of depression" |
| Norepinephrine (locus coeruleus) | Arousal, selective attention | Focus, orienting, wakefulness | "I need more concentration" as an isolated problem |
| GABA | Tonic and phasic inhibition | Calm, modulation of anxiety | "Natural GABA" as a magic supplement |
How these three fit with the rest of the brain
The three systems above need scaffolding that rarely gets the spotlight in class but without which the picture collapses: GABA, glutamate and acetylcholine. They are covered next, because understanding the whole family changes how you hear a client talk about "chemistry" and about "character."
A useful order of magnitude: dopamine, serotonin and norepinephrine are neuromodulators, which adjust the firing probability of circuits that are already organized. GABA and glutamate do the fine synaptic work, one inhibiting and the other exciting. Acetylcholine is not "memory" as a property, but without it consolidating new declarative memories is thought to become very difficult.
Three directions for going deeper before moving on:
- The reward system and dopamine in psychology: pathways and behavioral addiction.
- The four brain lobes and their functions: to know where each system acts, so that "dopamine" is never discussed without a place.
- Neuroplasticity: how the brain reorganizes itself, which connects these systems with learning.
GABA: the brain's main brake
GABA (gamma-aminobutyric acid) is the main inhibitory transmitter of the adult brain. It acts on GABA-A receptors (fast, ion-channel receptors) and GABA-B receptors (slower, metabotropic). Its job is not to create calm but to keep excitation from running unchecked.
Benzodiazepines are positive allosteric modulators of GABA-A receptors: they do not activate the receptor on their own but enhance the effect of the GABA that is already there. That is why they are sedating and anxiety-reducing, and why stopping them abruptly after long use can cause rebound symptoms. Anxiety is better understood as a matter of balance between excitation and inhibition across many circuits than as "not enough GABA."
In anxiety, the issue is not simply that GABA is missing but the balance between glutamatergic excitation and GABAergic inhibition in circuits that include the extended amygdala and the medial prefrontal cortex. GABA-A receptors come in several subtypes, and animal research suggests they contribute differently to sedative and anxiety-reducing effects, which is one reason benzodiazepines are not the only possible way to modulate GABA.
This also sharpens a common clinical formulation. A person who systematically avoids feared situations does not have a "broken calm system." Exposure-based treatment is better described at the level of learning, through new inhibitory associations that compete with the original fear (Craske et al., 2014), than as a repair of GABA itself. They are different levels of explanation for the same phenomenon.
Technical note. The action of benzodiazepines on GABA-A is allosteric: they do not activate the receptor directly but increase the affinity of endogenous GABA for its site. This explains why they do not produce general anesthesia on their own, and why abrupt discontinuation can cause rebound anxiety: during chronic use the system becomes desensitized to endogenous GABA.
Glutamate: the main accelerator and a key to learning
Glutamate is the main excitatory transmitter in the central nervous system. It acts on AMPA, NMDA, kainate and metabotropic receptors. The NMDA receptor is a coincidence detector: it opens only when glutamate is bound and the postsynaptic cell is already depolarized. That property is central to long-term potentiation (LTP), a long-lasting strengthening of synapses that is a leading model of how memories are stored (Bliss & Collingridge, 1993). In a classic experiment, rats given an NMDA-receptor blocker showed impaired spatial learning and blocked LTP in the hippocampus (Morris et al., 1986).
In more detail: AMPA receptors are fast and depolarizing, NMDA receptors are slower and voltage dependent, and metabotropic receptors (mGluR) modulate activity rather than carrying the fast signal. The classroom key is NMDA, because its activation together with depolarization unblocks calcium entry, which starts LTP.
The clinical principle is balance: GABA brakes, glutamate accelerates, and healthy function depends on both. Memantine, which acts on NMDA receptors, is used in moderate to severe Alzheimer's disease, as a standard pharmacology textbook will show.
One way to remember it: GABA brakes, glutamate accelerates, and learning happens when the two interact precisely. Without inhibition, excitation saturates; without excitation, there is no signal to modulate.
There is also a second clinical layer. The GABA–glutamate balance does not maintain itself: it depends on intact inhibitory interneurons (many of them GABAergic), on energy supply and on inflammatory state. In conditions such as epilepsy or alcohol withdrawal, hyperexcitability is generally described not as glutamate rising in isolation but as inhibition falling and no longer containing it. This logic of balance, rather than "one molecule per disorder," underlies several current treatments: benzodiazepines enhance endogenous GABA, some antiepileptic drugs reduce excitatory transmission, and memantine partially antagonizes NMDA receptors (all standard pharmacology textbook material).
Technical note. LTP requires temporal coincidence: glutamate released at the synapse plus postsynaptic depolarization that unblocks the NMDA channel. This requirement is often compared to the behavioral principle of temporal contiguity, the idea that a stimulus and its consequence must occur close together in time to be associated (see classical conditioning). The comparison is an analogy, not a proven one-to-one mechanism.
Acetylcholine: encoding, attention and muscle
Acetylcholine (ACh) is the transmitter of the neuromuscular junction, where it triggers muscle contraction. In the brain, cholinergic neurons in the basal forebrain project to the cortex and hippocampus and are important for attention and memory. Hasselmo (2006) describes how different levels of ACh suit different memory stages: higher levels during waking favor encoding of new information, and lower levels during slow-wave sleep are thought to favor consolidation. That is one reason sleep matters for learning.
Two projection systems are worth knowing: the basal nucleus of Meynert, which projects to the cortex and hippocampus, and the pedunculopontine tegmentum, which projects to the thalamus and takes part in REM sleep. Loss of basal forebrain cholinergic neurons is a well-documented feature of Alzheimer's disease and the basis of the cholinergic hypothesis of its cognitive decline (Francis et al., 1999).
For a student, this has a concrete reading: REM sleep and slow-wave sleep play different but complementary roles in consolidation, and acetylcholine operates differently in each. Sleep deprivation is therefore not just "tiredness"; it is plausibly associated with more fragile consolidation of what was learned.
Popular oversimplification: "memory in a pill." Memory depends on intact cortical and hippocampal circuits, several transmitter systems, sleep and spaced practice, and no single component guarantees it.
The realistic version is more modest: an intact cortico-hippocampal architecture, working acetylcholine, enough sleep and spaced repetition. If any of the four fails, consolidation suffers, and none of them guarantees it alone.
One further distinction helps in class. In the hippocampus, acetylcholine modulates the encoding of new episodic memories (Hasselmo, 2006), while in the cortex cholinergic input is closely tied to sustained attention. The two effects operate in parallel and interact, which helps explain why attention problems and memory problems tend to appear together in neurodegenerative conditions such as Alzheimer's disease.
Clinical context: what psychiatric drugs teach, and what they do not
This section describes how clinical practice makes use of neurotransmitter systems; it does not replace medical judgment. Pharmacology belongs to the psychiatrist and other prescribers. For a psychology student, the goal is to understand it as systems, not to prescribe.
SSRIs (selective serotonin reuptake inhibitors) block the serotonin transporter on the presynaptic neuron, increasing the availability of serotonin in the synaptic cleft. Their clinical effect takes weeks, which suggests that the benefit does not come from an immediate rise in serotonin but from slower adaptive changes downstream, such as changes in receptor regulation, neuroplasticity and emotional processing (Harmer et al., 2017). This fits the evidence discussed above: the simple monoamine hypothesis explains depression poorly, yet serotonergic modulation remains a useful pharmacological entry point for some conditions.
Levodopa in Parkinson's disease illustrates another principle: replenishing dopamine in the striatum improves motor symptoms but does not stop the underlying loss of dopamine neurons. It also exposes a trap. The motor dopamine system is distinct from the mesolimbic system, and the same neurotransmitter serves different functions in different circuits.
Propranolol, a beta-blocker, reduces the peripheral effects of noradrenergic activation, such as a racing heart and tremor. That is why it is used to attenuate the physiological response in some situations, such as performance anxiety, although its effect on emotional memory is debated.
Three rules to take away:
- A psychiatric drug modifies a system; it does not erase a behavior.
- Clinical latency is usually longer than the time needed for the immediate neurochemical change.
- The same drug can help or harm depending on the circuit it acts on.
One distinction that gets mixed up in class deserves emphasis: modulation and causation are not the same thing. Saying "SSRIs modulate serotonin" is precise. Saying "depression is caused by a serotonin deficit" is an oversimplification that the evidence has weakened, although it remains alive in popular writing. Keeping the distinction protects you from buying reductionist models and leaves you steadier when a client arrives convinced that their suffering is "just chemistry."
Health note. Educational content for students. It is not medical advice. For questions about medication, ask a licensed prescriber. If you or someone you know is in crisis, call your local emergency number; findahelpline.com lists services by country.
Common mistakes that cost points on exams
- Saying "low serotonin causes depression." The evidence does not support a simple causal story (Moncrieff et al., 2022). Say that serotonergic drugs modulate a system and that the mechanism of therapeutic benefit is not settled.
- Equating dopamine with pleasure. It is better tied to prediction and motivation (Berridge & Robinson, 2016).
- Labeling a neurotransmitter as simply excitatory or inhibitory. The receptor and the circuit decide.
- Treating disorders as "chemical imbalances." The phrase hides the role of circuits, learning, stress and context.
- Assigning one function to one molecule. Systems overlap: attention involves norepinephrine, dopamine and acetylcholine; mood involves more than serotonin.
- Confusing a neuromodulator with a fast transmitter. Glutamate and GABA carry fast synaptic signals; dopamine, serotonin and norepinephrine mostly tune circuits.
- Mixing up levels of explanation. A molecule (biochemical), a receptor (cellular), a circuit (systems), an action (behavior) and a context (social) are different levels. Confusing them yields statements that sound convincing and are wrong.
- Assuming more neurotransmitter means better function. Overloading a system can produce adaptations such as receptor down-regulation or tolerance, or effects opposite to the ones sought.
- Claiming that neurochemistry explains all behavior. It invites the naturalistic fallacy, the slide from "the brain does X" to "X is therefore good or unavoidable."
A note on the "chemical imbalance" error: when someone says "my anxiety is chemical, so there is nothing I can do," neurochemistry is being used as a ceiling instead of as context. Chemistry is the terrain, not the destiny. A dysregulated system is not an unchangeable one; it calls for calibrated intervention, not for giving up on the problem.
And a note on the "neurochemistry explains everything" error: there is constant media pressure to translate behavior into neurochemistry because brain images are visually convincing. But a patch of activation on a functional MRI scan is not a molecule. It is a change in a BOLD signal, averaged over many trials in a group of people. Using it as a picture of one person's neurotransmitter is an oversimplification that is cheap to repeat and costly to correct.
A student's question
"If chemical explanations are too simple, why do psychiatric drugs that act on neurotransmitters work?" A drug that changes a system can change behavior without the original problem being that system's deficit. Aspirin relieves a headache but headaches are not caused by too little aspirin. The better question is what the drug changes downstream, in circuits and in how people process emotion and information, which is an active research topic (Harmer et al., 2017).
Putting it together for clinical work
When a client says "I am anxious because I have low serotonin" or "I'm addicted to dopamine," they are translating distress into neurochemical language. That move is not useless: it gives a name to something diffuse and offers an explanation. A clinician's task is not to correct it with a lecture but to open the conversation toward the systems that can actually be worked on.
Three reframes worth practicing in role-play before supervision:
- From "I don't have serotonin" to "what I see is that your mood-regulation system is overloaded at this point in your life."
- From "I'm addicted to dopamine" to "your reward system learned that this specific behavior was the most accessible source of relief."
- From "it's my chemistry" to "it's your biology in context, and context can be worked on."
Clinical reminder. The phrase "it is chemical" closes conversations; the phrase "it is biological in context" opens them. A client who holds the first view tends to leave less room for psychological intervention than one who holds the second.
How to study this topic without over-memorizing
To avoid the shortcut of knowing the substances instead of the systems, three moves help while studying:
- Ask about the circuit before the molecule. Not "what does serotonin do?" but "which serotonergic circuits are active in this condition, and what do they modulate?"
- Separate levels of analysis. Biochemical (molecule), cellular (receptor), systems (circuit), behavioral (action) and social (context). Mixing levels produces statements that are technically wrong but very convincing in class.
- Return to the language of the clinic. "Attentional sensitivity," "mood regulation" and "behavioral inhibition" are clinical categories that map onto several neurotransmitters at once. Use the clinic as the anchor and neurochemistry as the support, not the other way around.
Excitatory, inhibitory and modulatory: the receptor decides
A classic way to organize neurotransmitters is by their effect on the receiving neuron: excitatory ones increase the probability that it fires a nerve impulse, and inhibitory ones reduce it. The brain works through the balance between the two.
- Excitatory: glutamate in most brain synapses; acetylcholine at the neuromuscular junction, where it triggers contraction; aspartate also has excitatory action.
- Inhibitory: GABA in the brain; glycine in the spinal cord and brainstem.
- Modulatory: dopamine, serotonin and norepinephrine, which can excite or inhibit depending on the receptor and the circuit.
The exam-ready rule: the effect depends on the receptor. Acetylcholine excites skeletal muscle through nicotinic receptors, and through a different (muscarinic) receptor it slows the heart.
Summary table
| Transmitter | Functional type | Key circuits | Behavior modulated | Common oversimplification |
|---|---|---|---|---|
| Dopamine | Neuromodulator | Ventral tegmental area to nucleus accumbens; substantia nigra to striatum; ventral tegmental area to prefrontal cortex | Reward prediction, motivation, movement | "The pleasure chemical" |
| Serotonin (5-HT) | Neuromodulator | Raphe nuclei (to cortex and limbic regions); most of the body's serotonin is made in the gut | Mood, impulsivity, sleep, appetite, aggression | "Low serotonin causes depression" |
| Norepinephrine | Neuromodulator | Locus coeruleus (to cortex and thalamus) | Arousal, attention, stress response | "The focus chemical" |
| GABA | Inhibitory (ionotropic and metabotropic) | Interneurons, cerebellum, thalamus | Inhibition, modulation of anxiety | "The calming chemical" |
| Glutamate | Excitatory (ionotropic and metabotropic) | Cortex, hippocampus, striatum | Excitation, plasticity, learning | "Just the excitement chemical" |
| Acetylcholine | Neuromodulator and fast transmitter | Basal forebrain (basal nucleus of Meynert), pedunculopontine and laterodorsal tegmentum; neuromuscular junction | Attention, memory, REM sleep, muscle contraction | "The memory chemical" |
Frequently asked questions
What is the "most important" neurotransmitter for behavior?
None. Behavior emerges from systems, not from isolated substances. Asking which one is most important is like asking which gear makes a clock work: it depends on the hour you want to read.
Does "low" serotonin cause depression?
Not as a sufficient explanation. The simple monoamine hypothesis is incomplete (Moncrieff et al., 2022). Serotonin modulates affective sensitivity, sleep regulation, impulsivity and aggression, and its alteration is one factor among several. That is why SSRIs help some people and not others.
Do GABA or tryptophan supplements help with anxiety or depression?
The evidence is limited, and the mechanisms are not equivalent to pharmacological modulation. SSRIs block the transporter; supplements provide a precursor or the molecule itself. That a precursor raises the overall availability of serotonin does not mean it corrects a clinical dysregulation. Decisions about supplements are best discussed with a licensed prescriber.
Is dopamine "used up" by pleasure, so that more of it is needed?
No. Dopamine is not a reserve that runs out; it is a system that adapts. After an intense stimulus there can be a period of reduced responsiveness, but the "tank" image is a metaphor, not a description of how the system works.
Do neurotransmitters determine personality?
No. They modulate probabilities; they do not determine outcomes. Two people with similar neurochemical profiles can behave differently depending on learning history, context and brain architecture. Saying "I am anxious because I have little serotonin" mixes levels of analysis.
Which neurotransmitters are most involved in learning?
Glutamate (through NMDA receptors) is central to long-term potentiation, and acetylcholine modulates encoding and consolidation. Dopamine marks salience and reward prediction, which filters what is worth learning. Norepinephrine and serotonin modulate arousal and the emotional consolidation of learning.
Why do psychiatric drugs take weeks to work if they change neurotransmitters right away?
Because behavioral change depends on downstream adaptations: receptor regulation, gene expression, neuroplasticity and modulation of circuits. Raising serotonin in the synapse today is not the same as reorganizing a circuit over weeks.
What are the main neurotransmitters?
Dopamine, serotonin, norepinephrine, GABA, glutamate and acetylcholine are the six most commonly taught in psychology courses. Others include glycine, endorphins and histamine.
What is the difference between a neurotransmitter and a hormone?
Neurotransmitters act across a synapse over a very short distance. Hormones are released into the bloodstream and act on distant targets. Some molecules, such as norepinephrine, do both.
Does dopamine cause addiction?
Dopamine is involved in how cues and rewards drive motivation, but addiction involves learning, stress, genetics, environment and other neurotransmitter systems.
Is depression a chemical imbalance?
That framing is not supported by current evidence as a simple explanation. Depression is heterogeneous, and research points to many contributing factors.
What is long-term potentiation?
A lasting increase in the strength of a synapse after intense activity, thought to underlie some forms of learning and memory. NMDA receptors play a central role.
What to take to your next class or supervision session
Before your next class or supervision session, here are five key ideas worth being able to state in one or two sentences:
- Behavior is a property of systems, not of isolated neurotransmitters.
- Dopamine predicts and motivates; it does not "produce pleasure."
- Serotonin modulates mood and impulsivity; it is not the happiness molecule.
- GABA brakes, glutamate accelerates, and acetylcholine modulates attention and consolidation.
- Clinical practice uses these systems for specific purposes; no drug "erases" a behavior, it modulates it.
A question worth carrying into supervision, and adding to your own bank: which circuit, in this case, is sustaining the symptom? Not "which neurotransmitter is missing?" but "which system stopped regulating, and under what contextual conditions is that dysregulation maintained?"
Another distinction worth installing before reading papers is the one between neurotransmission and neuromodulation. Neurotransmission operates at a fast synaptic scale, in milliseconds, point to point. Neuromodulation operates over minutes to hours, diffusely, changing the firing probability of whole populations of neurons. Dopamine, serotonin and norepinephrine are typical neuromodulators; GABA and glutamate are classic synaptic transmitters. This difference in time scale changes what to expect from a pharmacological intervention and why its behavioral effect is not immediate. Once the difference is clear, several common misunderstandings about the "speed" of psychiatric drugs stop making sense.
To tie the circuit to related reading, two complementary topics help: the distinction between intrinsic and extrinsic motivation, which keeps dopamine from being confused with willpower, and the historical tour of motivation theories, which places neurochemistry in a broader frame where human motivation is a biopsychosocial phenomenon, not the product of one molecule.
The map, not the molecule
If you have read this far, what is worth keeping is not the list of neurotransmitters but the map of relations among them. Dopamine, serotonin and norepinephrine are modulators that give tone and direction to circuits already organized by GABA, glutamate and acetylcholine as architecture. Behavior is the sound the orchestra makes when it plays, and social and learning context decides the score.
Two questions are more productive than a rote recitation: which circuit is sustaining this symptom, and which condition of the environment keeps it going? With those two in mind, the rest of the neurochemical map becomes a tool instead of a dogma.
To go deeper on a single system, there are specific topics to pursue: reward and dopamine, organization by lobes, neuroplasticity, intrinsic motivation and theories of motivation. This guide works as a hinge between synaptic biology and clinical psychology; those topics work as a zoom on each of the systems that were only touched here.
One last practical note: the next time you read a headline about "the molecule of" some behavior, train the reflex of looking for the system, the circuit, the level of analysis and the population studied. If the headline collapses into a single molecule, it is often a simplification. If it names a system and connects it to a bounded, replicable behavioral effect, the finding is more likely to be serious. That is the difference between clickbait and a fact you can bring to class or to supervision without it falling apart at the first question.
Something else worth doing while studying: build your own table with three columns (neurotransmitter, system it integrates, behavior it modulates) and another with three columns (molecule, target circuit, clinical example). Together, the two tables work more clearly than a linear summary, because they force you to keep the molecular level apart from the behavioral level. When someone asks "what does dopamine do?", the tables let you answer "it depends on the system and the circuit," which is the honest answer.
Keep reading
- The four brain lobes and their functions — where these systems act.
- Classical vs. operant conditioning — the learning principles that reward prediction errors relate to.
- Attention: types and main theories — the cognitive side of arousal and norepinephrine.
References
- Aston-Jones, G., & Cohen, J. D. (2005). An integrative theory of locus coeruleus-norepinephrine function: Adaptive gain and optimal performance. Annual Review of Neuroscience, 28, 403–450. https://doi.org/10.1146/annurev.neuro.28.061604.135709
- Berger, M., Gray, J. A., & Roth, B. L. (2009). The expanded biology of serotonin. Annual Review of Medicine, 60, 355–366. https://doi.org/10.1146/annurev.med.60.042307.110802
- Berridge, K. C., & Robinson, T. E. (1998). What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience? Brain Research Reviews, 28(3), 309–369. https://doi.org/10.1016/S0165-0173(98)00019-8
- Berridge, K. C., & Robinson, T. E. (2016). Liking, wanting, and the incentive-sensitization theory of addiction. American Psychologist, 71(8), 670–679. https://doi.org/10.1037/amp0000059
- Bliss, T. V. P., & Collingridge, G. L. (1993). A synaptic model of memory: Long-term potentiation in the hippocampus. Nature, 361(6407), 31–39. https://doi.org/10.1038/361031a0
- Cowen, P. J., & Browning, M. (2015). What has serotonin to do with depression? World Psychiatry, 14(2), 158–160. https://doi.org/10.1002/wps.20229
- Craske, M. G., Treanor, M., Conway, C. C., Zbozinek, T., & Vervliet, B. (2014). Maximizing exposure therapy: An inhibitory learning approach. Behaviour Research and Therapy, 58, 10–23. https://doi.org/10.1016/j.brat.2014.04.006
- Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999). The cholinergic hypothesis of Alzheimer's disease: A review of progress. Journal of Neurology, Neurosurgery & Psychiatry, 66(2), 137–147. https://doi.org/10.1136/jnnp.66.2.137
- Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017). How do antidepressants work? New perspectives for refining future treatment approaches. The Lancet Psychiatry, 4(5), 409–418. https://doi.org/10.1016/S2215-0366(17)30015-9
- Hasselmo, M. E. (2006). The role of acetylcholine in learning and memory. Current Opinion in Neurobiology, 16(6), 710–715. https://doi.org/10.1016/j.conb.2006.09.002
- Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2022). The serotonin theory of depression: A systematic umbrella review of the evidence. Molecular Psychiatry, 28(8), 3243–3256. https://doi.org/10.1038/s41380-022-01661-0
- Morris, R. G. M., Anderson, E., Lynch, G. S., & Baudry, M. (1986). Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature, 319(6056), 774–776. https://doi.org/10.1038/319774a0
- Salamone, J. D., & Correa, M. (2012). The mysterious motivational functions of mesolimbic dopamine. Neuron, 76(3), 470–485. https://doi.org/10.1016/j.neuron.2012.10.021
- Sara, S. J. (2009). The locus coeruleus and noradrenergic modulation of cognition. Nature Reviews Neuroscience, 10(3), 211–223. https://doi.org/10.1038/nrn2573
- Schultz, W. (1998). Predictive reward signal of dopamine neurons. Journal of Neurophysiology, 80(1), 1–27. https://doi.org/10.1152/jn.1998.80.1.1
- Schultz, W., Dayan, P., & Montague, P. R. (1997). A neural substrate of prediction and reward. Science, 275(5306), 1593–1599. https://doi.org/10.1126/science.275.5306.1593